The global oncology pharmaceutical industry is undergoing a cyclical adjustment, gradually moving away from the phase of extensive capital-driven expansion. A value-based R&D logic centered on original technological strength and unmet clinical needs has become a global consensus. The four major frontier technologies—ADCs, bispecific antibodies, PROTACs, and cell therapies—are simultaneously accelerating their iteration, reshaping the landscape of global oncology drug innovation.Among the four major therapeutic arenas, cell therapy has reached a pivotal moment of qualitative transformation, with TIL therapy achieving a critical breakthrough: overseas products have successfully achieved commercialization, while domestic pipelines, such as Juncell Therapeutics’ GC101, have been featured as a “Late-Breaking Abstract” at the 2026 ASCO Annual Meeting. This achievement not only demonstrates key Phase II clinical data recognized internationally but also lowers the treatment threshold through engineering innovations, addressing long-standing implementation bottlenecks of cell therapies—including high clinical barriers, complex manufacturing processes, and high-cost structures—thereby remedying the safety limitations associated with traditional TIL therapy.Coupled with the intensified industrialization efforts of global pharmaceutical companies in cell therapy for solid tumors, TIL is poised to cross the commercialization watershed, unlocking new growth potential in immunotherapy for solid tumors.Multiple Rounds of Support from Existing Shareholders Coupled with Efficient R&D AdvancementJuncell Therapeutics at the Forefront of Global TIL Therapy IndustrializationOn June 16, 2026, the official website of the Hong Kong Stock Exchange showed that Shanghai Juncell Therapeutics Co., Ltd. (hereinafter referred to as "Juncell Therapeutics") updated its prospectus materials, with CITIC Securities serving as its exclusive sponsor.In addition to updating the outcomes from this year’s ASCO in its prospectus, Juncell Therapeutics also disclosed its latest cash reserves. As of the end of 2025, the company’s cash balance amounted to RMB 309 million. As of the end of April 2026, the company’s unused credit facility totaled RMB 256 million.Another set of data shows that Juncell Therapeutics’ cash flows from financing activities amounted to RMB 231 million and RMB 302 million in 2024 and 2025, respectively. Of these amounts, the company received capital injections from shareholders totaling RMB 305 million in 2024 and RMB 233 million in 2025. The cumulative shareholder capital increases over the two years reached RMB 538 million, with multiple rounds of additional investment from existing shareholders such as the Kaitai group, Yuanhe group, and Furong group. This demonstrates that high-quality cell therapy companies continue to attract strong investor interest amid the shifting global capital landscape.With ample and sustainable funding reserves, coupled with its leading R&D advancement speed in the field of TIL therapy for solid tumors, Juncell Therapeutics is focusing on core assets at a faster pace, accelerating the commercialization process of GC101, and steadily seizing the first-mover market in solid tumor immunotherapy.Top-Level Commercialization Framework and Its Three PillarsJuncell Therapeutics has completed all preparations."The Art of War" emphasizes strategic planning, with its most famous maxim being "The supreme art of war is to subdue the enemy without fighting." The commercialization strategy of Juncell Therapeutics begins with the top-level design of its products.At the ASCO conference, GC101, hailed by international peers as a “next-generation therapy,” showcased China’s robust expertise in process innovation for cell therapies to the world.Juncell Therapeutics’ strategic choice for GC101 was, in essence, a proactive “dimensionality reduction”: voluntarily abandoning the IL-2 regimen that had served as the industry standard for three decades, deliberately reducing the intensity of lymphodepletion, and incorporating considerations such as “future patient costs” and “physician workload” into the design phase from the outset. While these decisions appeared at the time to be detours, in retrospect, they have precisely paved the shortest path to commercialization.This company has been directly addressing the challenges of “clinical implementation” and “industrialization” from the outset. For the first time, TIL therapy is poised to transform from a “highly sophisticated technology manageable only by a few top-tier centers in intensive care units (ICUs)” into a “routine treatment that can be administered in general wards by standard oncology departments.” The substantial reduction in the threshold for clinical use will directly determine the commercial potential ceiling of this cell therapy.After all, no matter how elegant a technology may be, if it fails to secure regulatory approval, cannot achieve commercial sales, or remains unaffordable, it remains merely a exhibit in the laboratory. The reason GC101 warrants a thorough analysis from a financial perspective is that Juncell Therapeutics has rarely managed to establish all three critical pillars of commercialization.First Fulcrum:Clinical Accessibility. GC101 has met its primary endpoint in the pivotal Phase II clinical trial for melanoma, with a Biologics License Application (BLA) scheduled for submission this year. Upon approval, GC101 will become the first marketed TIL cell therapy in China. The first-mover advantage should not be underestimated; elements such as brand mindshare, accumulated physician education, and market access windows are difficult for latecomers to replicate easily.More importantly, the optimized clinical protocol for GC101 eliminates the need for high-intensity lymphodepleting chemotherapy and IL-2 administration, significantly enhancing safety for patients. By no longer requiring intensive care unit (ICU) support, the therapy can be administered across a broader range of hospitals, substantially lowering both the threshold for clinical adoption and the demand on medical resources. This advancement establishes the accessibility foundation necessary for large-scale commercial implementation.Second Fulcrum:Industrialization Capability. Juncell Therapeutics has constructed a new TIL cell industrialization base in Jiading, Shanghai, with a total area exceeding 16,000 square meters, enabling standardized and replicable industrial-scale production. It is reported that Juncell Therapeutics obtained the first domestic production license for TIL cell pharmaceuticals in February this year. Prior to this, Juncell Therapeutics led the formulation of China’s first industry standard for TIL cells, not only continuously providing high-quality TIL products to patients but also leading the high-quality development of the industry.Third Fulcrum:Payment and Cost. At the end of 2025, the National Healthcare Security Administration released the first edition of the Innovative Drug Catalogue for Commercial Health Insurance, with CAR-T therapy taking the lead. This has opened a new payment channel for high-value cell therapies.The Critical Time Window Is Opening. Accompanying the Second Filing with the Hong Kong Stock Exchange Is the Determination of the Juncell Therapeutics Team: Always Adhering to Doing “the Difficult but Right Thing.”Continuously breaking through barriers, leveraging breakthroughs in proprietary foundational technologies to make high-value TIL therapies with curative potential “safer, more effective, and more accessible,” thereby benefiting more cancer patients; capitalizing on the dividends of engineering innovation to steadily drive the industry toward more universally applicable industrialization, gradually turning the once-distant dream of solid tumor cell therapy into reality.First Review | Shi Wanjia
Second Review | Li Fangchen
Third Review | Li Jingzhi
